PMID- 22151473
OWN - NLM
STAT- MEDLINE
DCOM- 20120917
LR  - 20211021
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 16
IP  - 5
DP  - 2012 May
TI  - Intermittent hypobaric hypoxia applicability in myocardial infarction prevention 
      and recovery.
PG  - 1150-4
LID - 10.1111/j.1582-4934.2011.01508.x [doi]
AB  - Intermittent hypobaric hypoxia (IHH) has been the focus of important research in 
      cardioprotection, and it has been associated with several mechanisms. 
      Intermittent hypobaric hypoxia inhibits prolyl hydroxylases (PHD) activity, 
      increasing the stabilization of hypoxia-inducible factor-1 (HIF-1) and activating 
      crucial adaptative genes. It has been hence suggested that IHH might be a simple 
      intervention, which may offer a thoughtful benefits to patients with acute 
      myocardial infarction and no complications. Nevertheless, several doubts exist as 
      to whether IHH is a really safe technique, with little to no complications in 
      post-myocardial infarction patients. Intermittent hypobaric hypoxia might produce 
      instead unfavourable changes such as impairment of vascular hemodynamics and 
      hypertensive response, increased risk of hemoconcentration and thrombosis, 
      cardiac rhythm perturbations, coronary artery disease and heart failure, insulin 
      resistance, steatohepatitis and even high-altitude pulmonary oedema in 
      susceptible or nonacclimatized patients. Although intermittent and chronic 
      exposures seem effective in cardioprotection, IHH safety issues have been mostly 
      overlooked, so that assorted concerns should be raised about the opportunity to 
      use IHH in the post-myocardial infarction period. Several IHH protocols used in 
      some studies were also aggressive, which would hamper their widespread 
      introduction within the clinical practice. As such, further research is needed 
      before IHH can be widely advocated in myocardial infarction prevention and 
      recovery.
CI  - (c) 2011 The Authors Journal of Cellular and Molecular Medicine (c) 2011 Foundation 
      for Cellular and Molecular Medicine/Blackwell Publishing Ltd.
FAU - Sanchis-Gomar, Fabian
AU  - Sanchis-Gomar F
AD  - Faculty of Medicine, Department of Physiology, University of Valencia, Valencia, 
      Spain. fabian.sanchis@uv.es
FAU - Vina, Jose
AU  - Vina J
FAU - Lippi, Giuseppe
AU  - Lippi G
LA  - eng
PT  - Journal Article
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
SB  - IM
MH  - *Air Pressure
MH  - *Altitude
MH  - Humans
MH  - Ischemic Preconditioning, Myocardial/*methods
MH  - Myocardial Infarction/*prevention & control/rehabilitation
PMC - PMC4365893
EDAT- 2011/12/14 06:00
MHDA- 2012/09/18 06:00
PMCR- 2012/05/01
CRDT- 2011/12/14 06:00
PHST- 2011/12/14 06:00 [entrez]
PHST- 2011/12/14 06:00 [pubmed]
PHST- 2012/09/18 06:00 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - 10.1111/j.1582-4934.2011.01508.x [doi]
PST - ppublish
SO  - J Cell Mol Med. 2012 May;16(5):1150-4. doi: 10.1111/j.1582-4934.2011.01508.x.